Potential strategies for the eradication of multidrug-resistant Gram-negative bacterial infections

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Frieden M. Antibiotic Resistance Threats In The United States (2013). www.his.org.uk/files/3713/7941/9908/Antibiotic_Resistance_Threats_in_the_United_States_2013.pdf.
  Google Scholar
• 2 O'Neill J. Vaccines And Alternative Approaches: Reducing Our Dependence On Antimicrobials (2016). http://amr-review.org/sites/default/files/Vaccines%20and%20alternatives_v4_LR.pdf.
  Google Scholar
• 3 Laxminarayan R, Duse A, Wattal C et al. Antibiotic resistance – the need for global solutions. Lancet Infect. Dis. 13(12), 1057–1098 (2013). •• Reveals the dramatic rise of Gram-negative resistance to antibiotics and identify key areas in which action is urgently needed.
  MedlineGoogle Scholar
• 4 Cantóna R, Horcajadad JP, Oliver A, Garbajosaa PR, Vila J. Inappropriate use of antibiotics in hospitals: the complex relationship between antibiotic use and antimicrobial resistance. Enferm. Infecc. Microbiol. Clin. 31(Suppl. 4), 3–11 (2013).
  MedlineGoogle Scholar
• 5 Health First Europe. EU Policy Recommendations on Increased Patient Safety and the Prevention of Healthcare Associated Infections (2015). http://www.healthfirsteurope.org/uploads/Modules/Newsroom/hfe-hcai-paper-08022012-print-quality-2.pdf.
  Google Scholar
• 6 UK 5 Year Antimicrobial Resistance (AMR) Strategy 2013– 2018 Annual Progress Report And Implementation Plan (2014). www.gov.uk/government/uploads/system/uploads/attachment_data/file/385733/UK_AMR_annual_report.pdf.
  Google Scholar
• 7 Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect. Medicin. Chem. 6, 25–64 (2014).
  MedlineGoogle Scholar
• 8 Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int. J. Antimicrob. Agents 46(3), 266–271 (2015).
  Medline CASGoogle Scholar
• 9 Conly JM, Johnston BL. Where are all the new antibiotics? The new antibiotic paradox. Can. J. Infect. Dis. Med. Microbiol. 16(3), 159–160 (2005).
  MedlineGoogle Scholar
• 10 Ventola CL. The antibiotic resistance crisis. Part 1: causes and threats. P T 40(4), 277–283 (2015).
  MedlineGoogle Scholar
• 11 Ledford H. FDA under pressure to relax drug rules. Nature 492(7427), 19 (2012).
  Medline CASGoogle Scholar
• 12 Rigel NW, Silhavy TJ. Making a beta-barrel: assembly of outer membrane proteins in Gram-negative bacteria. Curr. Opin. Microbiol. 15(2), 189–193 (2012).
  Medline CASGoogle Scholar
• 13 Schwechheimer C, Kuehn MJ. Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions. Nat. Rev. Microbiol. 13(10), 605–619 (2015).
  Medline CASGoogle Scholar
• 14 Galdiero S, Falanga A, Cantisani M et al. Microbe–host interactions: structure and role of Gram-negative bacterial porins. Curr. Protein. Pept. Sci. 13(8), 843–854 (2012). •• Reviews the role of porins in activating immunological responses and their influence within antibiotic resistance mechanisms.
  Medline CASGoogle Scholar
• 15 Brown L, Wolf JM, Prados-Rosales R, Casadevall A. Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi. Nat. Rev. Microbiol. 13(10), 620–630 (2015).
  Medline CASGoogle Scholar
• 16 Willis LM, Whitfield C. Structure, biosynthesis, and function of bacterial capsular polysaccharides synthesized by ABC transporter-dependent pathways. Carbohydr. Res. 378, 35–44 (2013).
  Medline CASGoogle Scholar
• 17 Blot N, Berrier C, Hugouvieux-Cotte-Pattat N, Ghazi A, Condemine G. The oligogalacturonate-specific porin KdgM of Erwinia chrysanthemi belongs to a new porin family. J. Biol. Chem. 277(10), 7936–7944 (2002).
  Medline CASGoogle Scholar
• 18 Delcour AH. Outer membrane permeability and antibiotic resistance. Biochim. Biophys. Acta 1794(5), 808–816 (2009). •• Outlines possible mechanisms for permeating the Gram-negative outer membrane and the bacterial pathways that modify its architecture to resist antibiotics.
  Medline CASGoogle Scholar
• 19 Band VI, Weiss DS. Mechanisms of antimicrobial peptide resistance in Gram-negative bacteria. Antibiotics 4(1), 18–41 (2015). •• Provides an overview of the biomolecular mechanisms utilized by Gram-negative bacteria to increase resistance to antimicrobial peptides.
  CASGoogle Scholar
• 20 Pelletier MR, Casella LG, Jones JW et al. Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of Acinetobacter baumannii. Antimicrob. Agents. Chemother. 57(10), 4831–4840 (2013).
  Medline CASGoogle Scholar
• 21 Cullen TW, Giles DK, Wolf LN, Ecobichon C, Boneca IG, Trent MS. Helicobacter pylori versus the host: remodeling of the bacterial outer membrane is required for survival in the gastric mucosa. PLoS. Pathog. 7(12), e1002454 (2011).
  Medline CASGoogle Scholar
• 22 Dalebroux ZD, Matamouros S, Whittington D, Bishop RE, Miller SI. PhoPQ regulates acidic glycerophospholipid content of the Salmonella typhimurium outer membrane. Proc. Natl Acad. Sci. 111(5), 1963–1968 (2014).
  Medline CASGoogle Scholar
• 23 Pagès JM, James CE, Winterhalter M. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat. Rev. Microbiol. 6(12), 893–903 (2008).
  Medline CASGoogle Scholar
• 24 Tängdén T, Adler M, Cars O, Sandegren L, Löwdin EJ. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model. Antimicrob. Chemother. 68(6), 1319–1326 (2013).
  Google Scholar
• 25 Venter H, Mowla R, Ohene-Agyei T, Ma S. RND-type drug efflux pumps from Gram-negative bacteria: molecular mechanism and inhibition. Front. Microbiol. 6, 377 (2015). •• Explores RND efflux pumps and the development of new compounds to limit their impact.
  MedlineGoogle Scholar
• 26 Sun J, Deng Z, Yan A. Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations. Biochem. Biophys. Res. Commun. 453(2), 254–267 (2014).
  Medline CASGoogle Scholar
• 27 Alvarez-Ortega C, Olivares J, Martínez JL. RND multidrug efflux pumps: what are they good for? Front. Microbiol. 4, 7 (2013).
  MedlineGoogle Scholar
• 28 Dubos RJ. Studies on a bacterial agent extracted from a soil Bacillus: I. preparation of the agent. Its activity in vitro. J. Exp. Med. 70(1), 1–10 (1939).
  Medline CASGoogle Scholar
• 29 Bahar AA, Ren D. Antimicrobial peptides. Pharmaceuticals 6(12), 1543–1575 (2013).
  MedlineGoogle Scholar
• 30 Laverty G, Gorman SP, Gilmore BF. The potential of antimicrobial peptides as biocides. Int. J. Mol. Sci. 12(10), 6566–6596 (2011).
  Medline CASGoogle Scholar
• 31 Giuliani A, Pirri G, Rinaldi AC. Antimicrobial peptides: the LPS connection. Methods Mol. Biol. 618, 137–154 (2010).
  Medline CASGoogle Scholar
• 32 Park CB, Kim HS, Kim SC. Mechanism of action of the antimicrobial peptide buforin-II: buforin-II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem. Biophys. Res. Commun. 244(1), 253–257 (1998).
  Medline CASGoogle Scholar
• 33 Bradshaw J. Cationic antimicrobial peptides: issues for potential clinical use. Bio. Drugs 17(4), 233–240 (2003).
  CASGoogle Scholar
• 34 Yu Z, Qin W, Lin J, Fang S, Qiu J. Antibacterial mechanisms of polymyxin and bacterial resistance. Biomed. Res. Int. 679109 (2015).
  MedlineGoogle Scholar
• 35 Velkov T, Roberts KD, Nation RL et al. Pharmacology of polymyxins: new insights into an ‘old’ class of antibiotics. Future Microbiol. 8(6), 711–724 (2013).
  CASGoogle Scholar
• 36 Liu YY, Wang Y, Walsh TR et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect. Dis. 16(2), 161–168 (2016).
  MedlineGoogle Scholar
• 37 Vaara M. Polymyxins and their novel derivative. Curr. Opin. Microbiol. 13(5), 574–581 (2010).
  Medline CASGoogle Scholar
• 38 Park SC, Park Y, Hahm HS. The role of antimicrobial peptides in preventing multidrug-resistant bacterial infections and biofilm formation. Int. J. Mol. Sci. 12(9), 5971–5992 (2011).
  Medline CASGoogle Scholar
• 39 Joo SH. Cyclic peptides as therapeutic agents and biochemical tools. Biomol. Ther. 20(1), 19–26 (2012).
  Medline CASGoogle Scholar
• 40 Zhang L, Dhillon P, Yan H, Farmer S, Hancock RE. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Antimicrob. Agents. Chemother. 44(12), 3317–3321 (2000).
  Medline CASGoogle Scholar
• 41 Kondejewski LH, Jelokhani-Niaraki M, Farmer SW et al. Dissociation of antimicrobial and hemolytic activities in cyclic peptide diastereomers by systematic alterations in amphipathicity. J. Biol. Chem. 274(19), 13181–13192 (1999).
  Medline CASGoogle Scholar
• 42 Goodwin D, Simerska P, Toth. Peptides as therapeutics with enhanced bioactivity. Cur. Med. Chem. 19(26), 4451–4461 (2012).
  Medline CASGoogle Scholar
• 43 Tängdén T. Combination antibiotic therapy for multi-drug resistant Gram-negative bacteria. Ups. J. Med. Sci. 119(2), 149–153 (2014).
  MedlineGoogle Scholar
• 44 Kim S, Lieberman TD, Kishony R. Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance. Proc. Natl Acad. Sci. 111(40), 14494–14499 (2014).
  Medline CASGoogle Scholar
• 45 Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with Gram-negative bacteria. Clin. Microbiol. Rev. 25(3), 450–470 (2012).
  Medline CASGoogle Scholar
• 46 Burgess DS. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin. Infect. Dis. 40(Suppl. 2), S99–S104 (2005).
  Medline CASGoogle Scholar
• 47 Morones-Ramirez RJ, Winkler JA, Spina CS, Collins JJ. Silver enhances antibiotic activity against Gram-negative bacteria. Sci. Transl. Med. 5(190), 190ra81 (2013).
  MedlineGoogle Scholar
• 48 Lee W, Kim KJ, Lee DG. A novel mechanism for the antibacterial effect of silver nanoparticles on Escherichia coli. Biometals 6, 1191–1201 (2014).
  Google Scholar
• 49 Ge L, Li Q, Wang M, Ouyang J, Li X, Xing MM. Nanosilver particles in medical applications: synthesis, performance, and toxicity. Int. J. Nanomedicine 9, 2399–2407 (2014).
  MedlineGoogle Scholar
• 50 Gupta SK, Nayak RP. Dry antibiotic pipeline: regulatory bottlenecks and regulatory reforms. J. Pharmacol. Pharmacother. 5(1), 4–7 (2014).
  MedlineGoogle Scholar
• 51 Bertheta J, Damiena P, Hamzeh-Cognassea H et al. Human platelets can discriminate between various bacterial LPS isoforms via TLR4 signaling and differential cytokine secretion. Clin. Immunol. 145(3), 189–200 (2012).
  MedlineGoogle Scholar
• 52 Nikado H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev. 67(4), 593–656 (2003).
  MedlineGoogle Scholar
• 53 Harvey M, Cave G. Co-administration of phospholipid emulsion with first dose bactericidal antibiotic may retard progression of the sepsis response in Gram-negative septicaemia. Med. Hypotheses 83(5), 563–565 (2014).
  Medline CASGoogle Scholar
• 54 Kunsmann L, Rüter C, Bauwens A et al. Virulence from vesicles: novel mechanisms of host cell injury by Escherichia coli O104:H4 outbreak strain. Sci. Rep. 5, 13252 (2015).
  Medline CASGoogle Scholar
• 55 Płóciennikowska A, Hromada-Judycka A, Borzęcka K, Kwiatkowska K. Co-operation of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling. Cell. Mol. Life. Sci. 72(3), 557–581 (2015).
  Medline CASGoogle Scholar
• 56 Schumann RR. Old and new findings on lipopolysaccharide-binding protein: a soluble pattern-recognition molecule. Biochem. Soc. Trans. 39(4), 989–993 (2011).
  Medline CASGoogle Scholar
• 57 Domingues MM, Lopes SC, Santos NC, Quintas A, Castanho MA. Fold-unfold transitions in the selectivity and mechanism of action of the N-terminal fragment of the bactericidal/permeability-increasing protein (rBPI₂₁). Biophys. J. 96(3), 987–996 (2009).
  Medline CASGoogle Scholar
• 58 Liu Y, Ni B, Ren JD et al. Cyclic limulus anti-lipopolysaccharide (LPS) factor-derived peptide CLP-19 antagonizes LPS function by blocking binding to LPS binding protein. Biol. Pharm. Bull. 34(11), 1678–1683 (2011).
  Medline CASGoogle Scholar
• 59 Landeta C, Blazyk JL, Hatahet F. Compounds targeting disulfide bond forming enzyme DsbB of Gram-negative bacteria. Nat. Chem. Biol. 11(4), 292–298 (2015).
  Medline CASGoogle Scholar
• 60 Dutton RJ, Boyd D, Berkmen M, Beckwith J. Bacterial species exhibit diversity in their mechanisms and capacity for protein disulfide bond formation. Proc. Natl Acad. Sci. 105, 11933–11938 (2008).
  Medline CASGoogle Scholar
• 61 Depuydt M, Messens J, Collet JF. How proteins form disulfide bonds. Antioxid. Redox. Signal 15(1), 49–66 (2011).
  Medline CASGoogle Scholar
• 62 Inaba K, Murakami S, Suzuki M et al. Crystal structure of the DsbB–DsbA complex reveals a mechanism of disulfide bond generation. Cell 127(4), 789–801 (2006).
  Medline CASGoogle Scholar
• 63 Hayashi S, Abe M, Kimoto M, Furukawa S, Nakazawa T. The DsbA–DsbB disulfide bond formation system of Burkholderia cepacia is involved in the production of protease and alkaline phosphatase, motility, metal resistance, and multi-drug resistance. Microbiol. Immunol. 44(1), 41–50 (2000).
  Medline CASGoogle Scholar
• 64 Opperman TJ, Kwasny SM, Kim HS et al. Characterization of a novel pyranopyridine inhibitor of the AcrAB efflux pump of Escherichia coli. Antimicrob. Agents. Chemother. 58(2), 722–733 (2014).
  MedlineGoogle Scholar
• 65 Dreier J, Ruggerone P. Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosa. Front. Microbiol. 6, 660 (2015).
  MedlineGoogle Scholar
• 66 Li XZ, Plésiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin. Microbiol. Rev. 28(2), 337–418 (2015).
  Medline CASGoogle Scholar
• 67 Puckett SE, Reese KA, Mitev GM et al. Bacterial resistance to antisense peptide phosphorodiamidate morpholino oligomers. Antimicrob. Agents Chemother. 56(12), 6147–6153 (2012).
  Medline CASGoogle Scholar
• 68 Robinson R. RNAi therapeutics: how likely, how soon? PLoS Biol. 2(1), e28 (2004).
  MedlineGoogle Scholar
• 69 Long TE, Williams JT. Cephalosporins currently in early clinical trials for the treatment of bacterial infections. Expert. Opin. Investig. Drugs 23(10), 1375–1387 (2014).
  Medline CASGoogle Scholar
• 70 Czaplewski L, Bax R, Clokie M et al. Alternatives to antibiotics – a pipeline portfolio review. Lancet Infect. Dis. 16(2), 239–251 (2016).
  Medline CASGoogle Scholar
• 71 Kohira N, West J, Ito A et al. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob. Agents Chemother. 60(2), 729–734 (2015).
  MedlineGoogle Scholar
• 72 Akbarzadeh A, Rezaei-Sadabady R, Davaran S et al. Liposome: classification, preparation, and applications. Nanoscale. Res. Lett. 8(1), 102 (2013).
  MedlineGoogle Scholar
• 73 Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug. Deliv. Rev. 65(1), 36–48 (2013).
  Medline CASGoogle Scholar
• 74 Colzi I, Troyan AN, Perito B et al. Antibiotic delivery by liposomes from prokaryotic microorganisms: Similia cum similis works better. Eur. J. Pharm. Biopharm. 94, 411–418 (2015).
  Medline CASGoogle Scholar
• 75 Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature Rev. Drug Discovery 4(2), 145–160 (2005).
  Medline CASGoogle Scholar
• 76 Nicolosi D, Scalia M, Nicolosi VM, Pignatello R. Encapsulation in fusogenic liposomes broadens the spectrum of action of vancomycin against Gram-negative bacteria. Int. J. Antimicrob. Agents 35(6), 553–5589 (2010).
  Medline CASGoogle Scholar
• 77 Elhissi AM, Ahmed W, Hassan IU, Dhanak VR, D'Emanuele A. Carbon nanotubes in cancer therapy and drug delivery. J. Drug Deliv. 837327 (2012).
  MedlineGoogle Scholar
• 78 Zhu X, Radovic-Moreno AF, Wu J, Langer R, Shi J. Nanomedicine in the management of microbial infection – overview and perspectives. Nano Today 9(4), 478–498 (2014).
  Medline CASGoogle Scholar
• 79 Usui Y, Haniu H, Tsuruoka S, Saito N. Carbon nanotubes innovate on medical technology. Med. Chem. 2(1), 1–6 (2012).
  CASGoogle Scholar
• 80 Rastogi V, Yadav P, Bhattacharya SS et al. Carbon nanotubes: an emerging drug carrier for targeting cancer cells. J. Drug Deliv. 670815 (2014).
  MedlineGoogle Scholar
• 81 Arias LR, Yang L. Inactivation of bacterial pathogens by carbon nanotubes in suspensions. Langmuir 25(5), 3003–3012 (2009).
  Medline CASGoogle Scholar
• 82 Yang C, Mamouni J, Tang Y, Yang L. Antimicrobial activity of single-walled carbon nanotubes: length effect. Langmuir 26(20), 16013–16019 (2010).
  Medline CASGoogle Scholar
• 83 Liu T, Tang H, Zhao J, Li D, Li R, Sun X. A study on the bactericidal properties of Cu-coated carbon nanotubes. Front. Mater. Sci. 1(2), 147–150 (2007).
  Google Scholar
• 84 McCloskey AP, Gilmore BF, Laverty G. Evolution of antimicrobial peptides to self-assembled peptides for biomaterial applications. Pathogens 3(4), 791–821 (2014).
  Medline CASGoogle Scholar
• 85 Zhang L, Dhillon P, Yan H, Farmer S, Hancock RE. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44, 3317–3321 (2000).
  Medline CASGoogle Scholar
• 86 Chapman R, Danial M, Koh ML, Jolliffe KA, Perrier S. Design and properties of functional nanotubes from the self-assembly of cyclic peptide templates. Chem. Soc. Rev. 41(18), 6023–6041 (2012).
  Medline CASGoogle Scholar
• 87 Fernandez-Lopez S, Kim HS, Choi EC et al. Antibacterial agents based on the cyclic D,L-alpha-peptide architecture. Nature 412(6845), 452–455 (2001).
  Medline CASGoogle Scholar
• 88 Rodríguez-Vázquez N, Ozores HL, Guerra A et al. Membrane-targeted self-assembling cyclic peptide nanotubes. Curr. Top. Med. Chem. 14(23), 2647–2461 (2014).
  Medline CASGoogle Scholar
• 89 Trudil D. Phage lytic enzymes: a history. Virol. Sin. 30(1), 26–32 (2015).
  Medline CASGoogle Scholar
• 90 Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage 1(2), 66–85 (2011).
  MedlineGoogle Scholar
• 91 Briers Y, Walmagh M, Van Puyenbroeck et al. Engineered endolysin-based “Artilysins” to combat multidrug-resistant Gram-negative pathogens. MBio 5(4), e01379–14 (2014).
  MedlineGoogle Scholar
• 92 Lukacik P, Barnard TJ, Hinnebusch BJ, Buchanan SK. Specific targeting and killing of Gram-negative pathogens with an engineered phage lytic enzyme. Virulence 4(1), 90–96 (2013). • Provides a proof of principle that phage lytic enzymes such as T4 lysozyme can be engineered to target Gram-negative bacteria.
  MedlineGoogle Scholar